Sanofi shores up neuro pipeline with deal for brain-penetrating Parkinson’s drug January 12, 2022 Auto Bot BioPharma, deals, neuroscience, Paris, Parkinson’s Disease, Pharma, Sanofi 0 Sanofi is the latest company to strike a deal for a Parkinson’s disease drug candidate that targets the protein alpha synuclein. The asset from ABL Bio is a bispecific antibody designed to penetrate the blood-brain barrier.